|
| Status |
Public on Feb 05, 2015 |
| Title |
LncRNA Expression Discriminates Karyotype and Predicts Survival in B-lymphoblastic Leukemia (Agilent) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Long non-coding RNAs (lncRNAs) have been found to play a role in gene regulation with dysregulated expression in various cancers. The precise role that lncRNA expression plays in the pathogenesis of B-acute lymphoblastic leukemia (B-ALL) is unknown. Therefore, unbiased microarray profiling was performed on human B-ALL specimens and it was determined that lncRNA expression correlates with cytogenetic abnormalities, which was confirmed by RT-qPCR in a large set of B-ALL cases. Importantly, high expression of BALR-2 correlated with poor overall survival and diminished response to prednisone treatment. In line with a function for this lncRNA in regulating cell survival, BALR-2 knockdown led to reduced proliferation, increased apoptosis, and increased sensitivity to prednisolone treatment. Conversely, overexpression of BALR-2 led to increased cell growth and resistance to prednisone treatment. Interestingly, BALR-2 expression was repressed by prednisolone treatment and its knockdown led to upregulation of the glucocorticoid response pathway in both human and mouse B-cells. Together, these findings indicate that BALR-2 plays a functional role in the pathogenesis and/or clinical responsiveness of B-ALL and that altering the levels of particular lncRNAs may provide a future direction for therapeutic development.
|
| |
|
| Overall design |
B-lymphoblastic leukemia is characterized by several translocations. In this study, we hybridized patient bone marrow samples from a total of 44 patients including 14 patients with B-ALL carrying a TEL-AML1 translocation, 15 patients with E2A-PBX1 translocation, and 15 patients carrying MLL translocations. The hybridizations were carried out in two sets, a discovery set and a validation set. In addition, we utilized samples from a human cell line (NALM6) and control CD10+CD19+ cells from human bone marrow.
|
| |
|
| Contributor(s) |
Fernando TR, Rodriguez-Malave N, Waters EV, Yan W, Casero D, Basso G, Pigazzi M, Rao DS |
| Citation(s) |
25681502 |
| Submission date |
Feb 04, 2015 |
| Last update date |
Oct 11, 2016 |
| Contact name |
Dinesh S Rao |
| E-mail(s) |
drao@mednet.ucla.edu
|
| Phone |
3108251675
|
| Organization name |
UCLA
|
| Department |
PATHOLOGY AND LABORATORY MEDICINE
|
| Street address |
750 CHARLES E YOUNG DRIVE, 12-272 FACTOR
|
| City |
LOS ANGELES |
| State/province |
CA |
| ZIP/Postal code |
90095 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL14550 |
Agilent-028004 SurePrint G3 Human GE 8x60K Microarray (Probe Name Version) |
|
| Samples (44)
|
|
| This SubSeries is part of SuperSeries: |
| GSE65647 |
LncRNA Expression Discriminates Karyotype and Predicts Survival in B-lymphoblastic Leukemia |
|
| Relations |
| BioProject |
PRJNA274652 |
Less...
More...